Highlights of Alzheimer’s Event Include New Use of PET Scans, a Blood Test and a Protein Imaging Development

Highlights of Alzheimer’s Event Include New Use of PET Scans, a Blood Test and a Protein Imaging Development
A plan to test a multi-dimensional, lifestyle-based approach to preventing cognitive decline and dementia in people at risk of Alzheimer's was one of the important revelations that surfaced at the 2017 Alzheimer’s Association International Conference, experts said. Other convention highlights that the Alzheimer’s Association identified included:
  • Interim results of a study on using PET scans of amyloid beta buildup to help manage patients' disease.
  • Interim results of a study dealing with whether a blood test can identify amyloid beta buildup.
  • Results of a study about a new imaging approach that researchers developed to investigate the pathways through which the tau protein spreads and to look at amyloid buildup over time. Both the tau and amyloid beta proteins play key roles in the development of Alzheimer's.
The two-year clinical trial will be the first to look at whether a range of lifestyle-related steps can be taken to prevent older people who are at risk of Alzheimer's from developing the disease. Researchers will enroll 2,500 older adults with no symptoms but who are considered at risk of cognitive decline, perhaps from developing Alzheimer’s. The trial will be called US POINTER, for U.S. study to PrOtect through a lifestyle INTErvention to Reduce risk.  It will build on Finland's FINGER study — the first randomized, controlled clinical trial that showed it is possible to use a multi-dimensional lifestyle approach to prevent older people from experiencing cognitive decline. FINGER stands for 
Subscribe or to access all post and page content.